Condition: Head and Neck Squamous Cell Carcinoma · Neoadjuvant Treatment · Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally advanced head and neck squamous cell carcinoma. The eligible patients are scheduled to administered neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin for two cycles. Radical resection will be performed in 3-4 weeks after two cycles of neoadjuvant therapy. The overall primary study hypothesis is that the novel neoadjuvant combination regime improves the pathological complete response (pCR) rate, with tolerable side effects.
This description comes directly from the study's public registry record.
Zhigang Liu, Dr. · 07562526192 · liuzhg9@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Fifth Affiliated Hospital of Sun Yat-sen University | Zhuhai, Guangdong, China | Recruiting |
| Zhigang Liu | Dongguan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05343325